98349-25-8

Basic information

• Product Name: ETHYL 1-CYCLOPROPYL-6,7-DIFLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLATE
• Synonyms: ETHYL 1-CYCLOPROPYL-6,7-DIFLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLATE;3-Quinolinecarboxylic acid, 1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo-, ethyl ester;Ethyl 1-Cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylate
• CAS NO: 98349-25-8
• Molecular Formula: C₁₅H₁₃F₂NO₃
• Molecular Weight: 293.27
• Mol File: 98349-25-8.mol
• Article Data: 21

Chemical Properties

• Melting Point: 229-230℃ (ethyl acetate )
• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: ETHYL 1-CYCLOPROPYL-6,7-DIFLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 1-CYCLOPROPYL-6,7-DIFLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLATE(98349-25-8)
• EPA Substance Registry System: ETHYL 1-CYCLOPROPYL-6,7-DIFLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLATE(98349-25-8)

Safety Data

• Hazardous Substances Data: 98349-25-8(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 98349-25-8 differently. You can refer to the following data:
1. Ethyl 1-Cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylate is an derivative of gatifloxacin (G250000), an antibacterial agent. Ethyl 1-Cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-3-quin olinecarboxylate was shown biological activities against Mycobacterium leprae and tubercluosis.
2. Ethyl 1-Cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylate is an derivative of gatifloxacin (G250000), an antibacterial agent. Ethyl 1-Cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylate was shown biological activities against Mycobacterium leprae and tubercluosis.

Upstream product

• 110600-97-0 ethyl 1-cyclopropyl-6-fluoro-1,4-dihydro-7-nitro-4-oxoquinoline-3-carboxylate 
• 101799-76-2 3-Cyclopropylamino-2-(2,4,5-trifluorbenzoyl)acrylsaeure-ethylester 
• 924-99-2 ethyl 3-(dimethylamino)acrylate 
• 88419-56-1 2,4,5-trifluorobenzoyl chloride 
• 64-17-5 ethanol 
• 93107-30-3 1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 623-47-2 propynoic acid ethyl ester 
• 96568-08-0 Ethyl 3-(Cyclopropylamino)-2-propenoate 
• 40648-44-0 β-ethoxyacrylic acid ethyl ester 
• 138998-46-6 ethyl 3-(dimethylamino)-2-(2,4,5-trifluorobenzoyl)prop-2-enoate 
• 13894-28-5 ethyl 3-(diethylamino)acrylate 
• 765-30-0 Cyclopropylamine 
• 1364518-39-7 C₁₆H₁₈F₃NO₃ 
• 446-17-3 2,4,5-trifluorobenzoic acid 

Downstream Products

• 105404-65-7 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate ethyl ester 
• 1429439-97-3 1-cyclopropyl-6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydroquinolin-3-carboxylic acid 
• 1429440-04-9 4-methoxybenzyl 5-chloro-1-cyclopropyl-6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydroquinolin-3-carboxylate 
• 1429440-05-0 5-chloro-1-cyclopropyl-6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 85721-33-1 ciprofloxacin 
• 1429439-96-2 4-methoxybenzyl 1-cyclopropyl-6,7-bis((4-methoxybenzyl)oxy)-4-oxo-1,4-dihydroquinolin-3-carboxylate 
• 1416988-36-7 1-cyclopropyl-6-fluoro-7-{4-[(4-fluoro-benzylamino)-methyl]-[1,2,3]triazol-1-yl}-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid 
• 1416988-35-6 7-[4-(benzylamino-methyl)-[1,2,3]triazol-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid 
• 1416988-34-5 1-cyclopropyl-6-fluoro-4-oxo-7-[4-(p-tolylamino-methyl)-[1,2,3]triazol-1-yl]-1,4-dihydro-quinoline-3-carboxylic acid 
• 1416988-33-4 1-cyclopropyl-6-fluoro-7-{4-[(4-methoxy-phenylamino)-methyl]-[1,2,3]triazol-1-yl}-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid 

Relevant articles and documents

Synthesis of Novel Ciprofloxacin-Based Hybrid Molecules toward Potent Antimalarial Activity

Antimalarial drug resistance is a serious obstacle in the persistent quest to eradicate malaria. There is a need for potent chemical agents that are able to act on drug-resistant Plasmodium falciparum populations at reasonable concentrations without any related toxicity to the host. By rational drug design, we envisaged to address this issue by generating a novel hybrid drug possessing two pharmacophores that can act on two unique and independent targets within the cell. We synthesized a new class of ciprofloxacin-based hybrid molecules, which have been integrated with acridine, quinolone, sulphonamide, and cinnamoyl pharmacophores (1-4). We realized a potent chloroquinolone-ciprofloxacin-based antimalarial hybrid (2, CQ-CFX) whose mechanism of action is unlike that of its parent molecules indicating a unique biological target. CQ-CFX is not only potent against CQ-resistant and susceptible strains of Plasmodium falciparum at low nanomolar concentrations (IC50 values are 63.17 ± 1.2 nM and 25.52 ± 4.45 nM, respectively) but is also not toxic to mammalian and bacterial systems up to 20 μM and 1 μM, respectively.

A Consolidated and Continuous Synthesis of Ciprofloxacin from a Vinylogous Cyclopropyl Amide

Ciprofloxacin is a broad-spectrum antibiotic that is recognized as one of the World Health Organization's Essential Medicines. It is particularly effective in the treatment of Gram-negative bacterial infections associated with urinary, respiratory, and gastrointestinal tract infections. A streamlined and high yielding continuous synthesis of ciprofloxacin has been developed, which employs a chemoselective C-acylation step that precludes the need for intermediate isolations, extractions, or purifications. The end-to-end process has a residence time of 4.7 min with a 15.8 g/h throughput at laboratory scale and an overall isolated yield of 83%.

STREAMLINED SYNTHESES OF FLUOROQUINOLONES

Methods of synthesizing fluoroquinolones such as ciprofloxacin are provided. The methods utilize affordable materials, reduce the number of synthesis steps and provide high yields.